Skip to main content

Main menu

  • Online first
    • Online first
  • Current issue
    • Current issue
  • Archive
    • Archive
  • Submit a paper
    • Online submission site
    • Instructions for authors
  • About the journal
    • About the journal
    • Editorial board
    • Instructions for authors
    • FAQs
    • Chinese Stroke Association
  • Help
    • Contact us
    • Feedback form
    • Reprints
    • Permissions
    • Advertising
  • BMJ Journals

User menu

  • Login

Search

  • Advanced search
  • BMJ Journals
  • Login
  • Facebook
  • Twitter
Stroke and Vascular Neurology

Advanced Search

  • Online first
    • Online first
  • Current issue
    • Current issue
  • Archive
    • Archive
  • Submit a paper
    • Online submission site
    • Instructions for authors
  • About the journal
    • About the journal
    • Editorial board
    • Instructions for authors
    • FAQs
    • Chinese Stroke Association
  • Help
    • Contact us
    • Feedback form
    • Reprints
    • Permissions
    • Advertising
Open Access

Coagulopathy reversal in intracerebral haemorrhage

Alexander Jacob Sweidan, Navneet Kaur Singh, Joseph Luke Conovaloff, Matthew Bower, Leonid I Groysman, Mohammad Shafie, Wengui Yu
DOI: 10.1136/svn-2019-000274 Published 30 March 2020
Alexander Jacob Sweidan
1 Neurology, University of California Irvine Medical Center, Orange, California, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Alexander Jacob Sweidan
Navneet Kaur Singh
2 Medicine, University of California Irvine Medical Center, Orange, California, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Joseph Luke Conovaloff
1 Neurology, University of California Irvine Medical Center, Orange, California, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Matthew Bower
1 Neurology, University of California Irvine Medical Center, Orange, California, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Matthew Bower
Leonid I Groysman
1 Neurology, University of California Irvine Medical Center, Orange, California, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mohammad Shafie
1 Neurology, University of California Irvine Medical Center, Orange, California, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Wengui Yu
1 Neurology, University of California Irvine Medical Center, Orange, California, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Wengui Yu
  • Article
  • Figures & Data
  • eLetters
  • Info & Metrics
  • PDF
Loading

Article Figures & Data

Figures

  • Tables
  • Figure 1
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 1

    Algorithm for the reversal of specific anticoagulants, including direct thrombin inhibitors, direct factor Xa inhibitors, warfarin and heparin. FFP, fresh frozen plasma; 4F-PCC,four factor prothrombin complex concentrate;ICH, intracerebral haemorrhage; INR, internationalnormalised ratio; IU, international unit; IV,intravenous; LMWH, low-molecular weight heparin; PCC,prothrombin complex concentrate.

Tables

  • Figures
  • Table 1

    Direct-acting oral anticoagulants (DOACs) and reversal

    DOACBrand nameMechanism of actionTime to onsett1/2 Reversal
    DabigatranPradaxaDirect thrombin inhibitor0.5–2 hour15 hoursIdarucizumab
    RivaroxabanXareltoFactor Xa inhibitor2–4 hour6–12 hour3F- and 4F-PCC, andexanet alfa
    ApixabanEliquis1–2 hour
    EdoxabanSavaysa, Lixiana1–2 hourAndexanet alfa
    BetrixabanBevyxxa3–4 hour24 hours
  • Table 2

    Anticoagulant reversal agents and their pharmacokinetics

    Anticoagulant reversalBrand nameTime to reverse coagulopathyt1/2 Terminal elimination t1/2
    IdarucizumabPraxbindMinutes47 m10 hours
    Prothrombin complex concentrateKcentra40 minfactor dependentfactor dependent
    Fresh frozen plasma…>24 hour
    Andexanet alfaAndexxaMinutes1 hour5–7 hour
  • Table 3

    Summary of trials for anticoagulant reversal and haemorrhage treatment

    TrialAnticoagulantAnticoagulant reversalPrimary endpointResults
    INCH25 VKAPCC, FFPPercentage of patients with INR <1.3 within 3 hours of treatmentPCC (vs FFP) had a higher rate of INR reversal
    UPRATE42–44 Rivaroxaban, apixaban4F-PCCHaemostasis rate4F-PCC reverses apixaban and rivaroxaban associated bleeding
    REVERSE-AD43 DabigatranIdarucizumabPercentage reversal at 4 hoursIdarucizumab reverses the effect of dabigatran for most patients (93%) within minutes
    ANNEXA-444 Rivaroxaban, apixabanAndexanet alfaChange in anti-Xa activity at 12 hours80% of those with DOAC associated ICH achieved excellent or good haemostasis 12 hours after andexanet alfa
    SPOTLIGHT and STOP-IT46 …rFVIIaParenchymal ICH volume expansion on head CT at 24 hoursrFVIIa does not improve radiographic findings
    • DOAC, direct-acting oral anticoagulant; FFP, fresh frozen plasma; ICH, intracerebral haemorrhage; INR, international normalised ratio; PCC, prothrombin complex concentrate; VKA, vitamin K antagonist.

PreviousNext
Back to top
Vol 5 Issue 1 Table of Contents
Stroke and Vascular Neurology: 5 (1)
  • Table of Contents
  • About the Cover
  • Index by author
Email

Thank you for your interest in spreading the word on Stroke and Vascular Neurology.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Coagulopathy reversal in intracerebral haemorrhage
(Your Name) has sent you a message from Stroke and Vascular Neurology
(Your Name) thought you would like to see the Stroke and Vascular Neurology web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Print
Alerts
Sign In to Email Alerts with your Email Address
Citation Tools
Coagulopathy reversal in intracerebral haemorrhage
Alexander Jacob Sweidan, Navneet Kaur Singh, Joseph Luke Conovaloff, Matthew Bower, Leonid I Groysman, Mohammad Shafie, Wengui Yu
Stroke and Vascular Neurology Mar 2020, 5 (1) 29-33; DOI: 10.1136/svn-2019-000274

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Cite This
  • APA
  • Chicago
  • Endnote
  • MLA
Loading
Coagulopathy reversal in intracerebral haemorrhage
Alexander Jacob Sweidan, Navneet Kaur Singh, Joseph Luke Conovaloff, Matthew Bower, Leonid I Groysman, Mohammad Shafie, Wengui Yu
Stroke and Vascular Neurology Mar 2020, 5 (1) 29-33; DOI: 10.1136/svn-2019-000274
Download PDF

Share
Coagulopathy reversal in intracerebral haemorrhage
Alexander Jacob Sweidan, Navneet Kaur Singh, Joseph Luke Conovaloff, Matthew Bower, Leonid I Groysman, Mohammad Shafie, Wengui Yu
Stroke and Vascular Neurology Mar 2020, 5 (1) 29-33; DOI: 10.1136/svn-2019-000274
Reddit logo Twitter logo Facebook logo Mendeley logo
Respond to this article
  • Tweet Widget
  • Facebook Like
  • Google Plus One
  • Article
    • Abstract
    • Introduction
    • Comparison of efficacy and safety between DOACs and VKAs
    • Reversal of VKA-related coagulopathy
    • Reversal of DOAC-related coagulopathy
    • On recombinant activated coagulation factor VII
    • Conclusion
    • Footnotes
    • References
  • Figures & Data
  • eLetters
  • Info & Metrics
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • Design of trials in lacunar stroke and cerebral small vessel disease: review and experience with the LACunar Intervention Trial 2 (LACI-2)
  • Anti-stroke biologics: from recombinant proteins to stem cells and organoids
  • Central post-stroke pain: advances in clinical and preclinical research
Show more Review

Similar Articles

 
 

CONTENT

  • Latest content
  • Current issue
  • Archive
  • eLetters
  • Sign up for email alerts
  • RSS

JOURNAL

  • About the journal
  • Editorial board
  • Recommend to librarian
  • Chinese Stroke Association

AUTHORS

  • Instructions for authors
  • Submit a paper
  • Track your article
  • Open Access at BMJ

HELP

  • Contact us
  • Reprints
  • Permissions
  • Advertising
  • Feedback form

© 2025 Chinese Stroke Association